Neucruit: Creating a platform to optimise participant recruitment for active COVID-19 vaccine trials, and future clinical and research trials.

临床研究试验保护患者免受实验性医学研究的影响，并确保新疫苗在规模化之前是安全有效的。平均而言，研究人员花费30%的研发费用用于招募参与者。当参与标准复杂时，可能需要长达7个月的时间才能找到参与者（CRM International-2011）。超过86%的临床研究由于受试者招募的延迟而延迟长达6个月，这意味着需要挽救生命的治疗的患者的延迟时间更长（Applied Clinical Trials-2004）。为了了解COVID-19的性质、影响和抑制，需要进行广泛的试验。试验可能包括疫苗接种和无症状患者测试，以了解疾病是如何传播的。目前约有150项COVID-19疫苗接种试验正在等待测试，平均每项试验需要650名参与者（Harden-2018）。世界各地的研究机构正试图紧急快速追踪疫苗。进入预先筛选的参与者网络将使疫苗接种迅速成为现实。Neucruit的创新将管理临床试验招募的优化平台与使用人工智能进行预选和匹配的智能算法相结合。Neucruit将通过基于网络的平台优化参与者招募，该平台将临床研究人员与大量患者进行匹配，在这个项目中，我们将把Neucruit平台开发成MVP，搭载至少9，000名参与者，并在三个实时的第三阶段COVID-19疫苗接种试验中测试我们的软件。

Clinical research trials protect patients from experimental medical research and ensure that new vaccinations are safe and effective before they're scaled. On average, researchers spend 30% of R&D securing participant recruitment. When the criteria for participation is complex, it can take up to 7 months to find participants (CRM International-2011). Over 86% of clinical research is delayed by up to 6-months due to delays in participant recruitment, translating into even longer delays for patients who need life-saving treatments (Applied Clinical Trials-2004).To understand the nature, effects and suppression of COVID-19, extensive trials are needed. Trials are likely to include vaccinations and asymptomatic patient testing to understand how the disease is spread. There are approximately 150 COVID-19 vaccination trials awaiting testing, requiring on average 650 participants per trial (Harden-2018). Research facilities around the world are attempting to urgently fast-track a vaccine. Access to a network of pre-screened participants will make vaccinations a reality, quickly.Neucruit's innovation combines an optimised platform for managing recruitment of clinical trials, with intelligent algorithms for pre-selection and matching using AI.Neucruit will optimise participant recruitment via a web-based platform, which matchmakes clinical researchers with a large population of patients, and digitalises contact time for risk reduction.In this project we will develop the Neucruit platform to MVP, onboard a minimum 9,000 participants and test our software in three live Phase III COVID-19 vaccination trials.